PART B - FEE(S) TRANSMITTAL

Complete and send this form, together with applicable fee(s), to: Mail

Mail Stop ISSUE FEE
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

or <u>Fax</u> (571) 273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as

indicate mainten	d unless corr ance fee notil	rected be fications.	low or directed otherwise	in Block 1, by (a	ı) specifying	a new c	orrespondence addres	s; and/or (b) indicating a se	parate "FEE ADDRESS" for	
CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)							Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying			
210	7590	05/12/2009					papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.			
MERCK AND CO., INC. P O BOX 2000 RAHWAY, NJ 07065-0907							Certificate of Mailing or Transmission I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.			
									(Depositor's name)	
									(Signature)	
		•							(Date)	
APPLICATION NO. FILING		FILING DATE	FIRST NAMED IN		D INVEN	TOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
	10/587.682 07/28/2006		07/28/2006	Wei Han				21515YP	8217	
TITLE OF INVENTION:							•			
HIV	NTEGRASE	INHIBIT	ORS							
A	APPLN. TYPE SM		SMALL ENTITY	ISSUE FEE		Pt	JBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE	
ne	onprovisional NO		\$1510		•	\$300	\$1810	08/12/2009		
EXAM		EXAMIN	TER	ART UNIT		C	LASS-SUBCLASS			
RAHMANI. NILOOFAR		ILOOFAR	1625			514-300000	-			
1. Chang CFR 1.3	ge of correspo	ondence a	ddress or indication of "F	ee Address" (37	•	_	the patent front page, l		117 1.	
Clarity Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.					(1) the names of up to 3 registered patent attorneys 1 Kenneth R. Walton or agents OR, alternatively,					
					(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is 3					
"Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Custon Number is required.					2 registered patent attorneys or agents. If no name is listed, no name will be printed.					
3. ASS10	GNEE NAMI	E AND R	ESIDENCE DATA TO E	E PRINTED ON	THE PATEN	T (print o	or type)			
PLE: recor	ASE NOTE: dation as set t	Unless a forth in 3	n assignee is identified be 7 CFR 3.11. Completion	clow, no assignce of this form is NO	data will app T a substitute	ear on t for filin	he patent. If an assig g an assignment.	mee is identified below, the	document has been filed for	
(A) NAME OF ASSIGNEE			(B) RESIDENCE: (CITY and STATE OR C			Y and STATE OR CO	DUNTRY)			
Merck & Co., Inc.				Rahway, New Jersey						
Please c	heck the appr	ropriate a	ssignee category or catego	ries (will not be pr	inted on the p	patent):	☐ Individual ☐ (Corporation or other private g	roup entity Government	
4a. The	following fee	(s) are en	closed:	4h	. Payment of	Fec(s):		 		
🖸 Issue Fee				A check in the amount of the fee(s) is enclosed.						
Publication Fee (No small entity discount permitted)				ed)						
Advance Order - # of Copies					The Director is hereby authorized by charge the required fee(s), or credit any overpayment, to Deposit Account Number13-2755					
		•	rom status indicated above	•	Π		4 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6			
			ALL ENTITY status. See					ALL ENTITY status. See 37 C		
NOTE: 1	The Issue Fee	e and Pub	lication Fee (if required) value of the United States Pate	vill not be accepted	i from anyon	e other t	re-apply any previous han the applicant; a reg	ly paid issue fee to the applic gistered attorney or agent; or	the assignee or other party in	
Authorized Signature /Kenneth R. Walton, Reg. No. 32,951/						-	Date July	24, 2009	The second secon	
Typed or printed name Kenneth R, Walton					Registration No. 32,951					
an applic submitti this form Box 145 Alexand	cation. Confident the complete and/or sugges of the complete and/or sugges of the confident and the co	dentiality leted appl sestions for a, Virgini 22313-14	is governed by 35 U.S.C. ication form to the USPT or reducing this burden, sla 22313-1450. DO NOT 150.	122 and 37 CFR O. Time will vary could be sent to the SEND FEES OR C	1.14. This co depending u chief Infor COMPLETEI	llection pon the mation C D FORM	is estimated to take 12 individual case. Any conficer, U.S. Patent and S TO THIS ADDRES	the public which is to file (ar minutes to complete, includ comments on the amount of the d Trademark Office, U.S. De S. SEND TO: Commissioner the displays a valid OMB control	ing gathering, preparing, and ime you require to complete partment of Commerce, P.O. for Patents, P.O. Box 1450,	

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- 2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- 5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- 6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.